A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours
F. Eskens(Erasmus MC), Elisabeth G.E. de Vries(University Medical Center Groningen)
Cited by 231
Related Papers
The Journey of Antibody–Drug Conjugates: Lessons Learned from 40 Years of Development
|Cancer Discovery|2024|167
The extrinsic apoptosis pathway and its prognostic impact in ovarian cancer
|Gynecologic Oncology|2009|54